Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) Director Richard Daly bought 28,025 shares of the company's stock in a transaction on Tuesday, November 10th. The stock was purchased at an average cost of $3.54 per share, for a total transaction of $99,208.50. Following the completion of the transaction, the director owned 28,025 shares in the company, valued at approximately $99,208.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Aquestive Therapeutics Stock Down 0.3%
AQST opened at $3.57 on Friday. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.93 and a fifty-two week high of $6.74. The business has a 50-day moving average of $4.40 and a 200-day moving average of $4.21.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $7.56 million during the quarter, compared to analyst estimates of $11.02 million. As a group, sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.
Hedge Funds Weigh In On Aquestive Therapeutics
Large investors have recently bought and sold shares of the stock. Bratton Capital Management L.P. bought a new stake in shares of Aquestive Therapeutics in the second quarter valued at about $40,813,585. BlackRock Inc. acquired a new position in Aquestive Therapeutics in the 2nd quarter valued at approximately $33,569,000. Bank of America Corp DE bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $6,941,000. Blue Owl Capital Holdings LP bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $3,923,000. Finally, Wasatch Advisors LP grew its holdings in shares of Aquestive Therapeutics by 57.8% during the 2nd quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company's stock worth $5,765,000 after purchasing an additional 507,527 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have issued reports on the stock. Wall Street Zen cut shares of Aquestive Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 7th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, October 16th. Weiss Ratings restated a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Thursday, October 15th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $11.00 price target on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $8.75.
Get Our Latest Stock Report on Aquestive Therapeutics
About Aquestive Therapeutics
(
Get Free Report)
Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company's products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
